To determine whether RUNX2 expression played a role in sensitivity to PLX4720, we treated 1205LU melanoma cells expressing non-silencing ShRNA, ShRUNX2-2 or ShRUNX2-3 with 10 μM PLX4720 for 72 hours and counted viable cells. Here, RUNX2 is linked to melanoma.